DBV Technologies (NASDAQ:DBVT) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report sent to investors on Friday. The brokerage issued a hold rating on the stock.

Separately, JMP Securities reissued a “market outperform” rating and issued a $10.00 price target on shares of DBV Technologies in a report on Friday, January 10th.

DBV Technologies Price Performance

Shares of DBV Technologies stock opened at $4.87 on Friday. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $8.32. The business has a 50 day moving average price of $4.37 and a 200 day moving average price of $3.81. The company has a market capitalization of $100.17 million, a P/E ratio of -1.08 and a beta of 0.71.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC purchased a new position in DBV Technologies S.A. (NASDAQ:DBVT) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies as of its most recent SEC filing. 71.74% of the stock is currently owned by institutional investors and hedge funds.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.